Toxoplasmosis drug, Daraprim, skyrockets in price

When used in combination with a sulfonamide and leucovorin, Daraprim is the preferred treatment among infectious disease specialists for toxoplasmosis. The drug was acquired from Impax Laboratories, Inc in early August by Turing Pharmaceuticals AG and the cost for patients instantly increased by some 5000 percent. The cost of the drug, the only FDA-approved treatment for the serious parasitic ["]